Cerenome (PSTV) Non-Current Deffered Revenue (2010 - 2023)
Plus Therapeutics (PSTV) posted quarterly Non-Current Deffered Revenue of $1.9 million for Q4 2023, up 17.1% year-over-year from $1.6 million in Q4 2022, and up 17.1% quarter-over-quarter from $1.6 million in Q4 2022.
Cerenome (PSTV) Non-Current Deffered Revenue (2010 - 2023) Analysis & Trends
Plus Therapeutics (PSTV) has reported Non-Current Deffered Revenue for 12 consecutive years, with $1.9 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Non-Current Deffered Revenue rose 17.1% year-over-year to $1.9 million; the TTM figure through Dec 2023 stood at $1.9 million (up 17.1% YoY), while the FY2023 annual figure was $1.9 million, up 17.1% from the prior year.
- Non-Current Deffered Revenue rose to $1.9 million in Q4 2023 per PSTV's latest filing, from $1.6 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $1.9 million in Q4 2023 and bottomed at $142000.0 in Q1 2019.
- Historically, Non-Current Deffered Revenue has averaged $1.2 million across 3 years, with a median of $1.6 million in 2022.
- Annual changes were most pronounced in 2019 — Non-Current Deffered Revenue surged 35.24% — and 2023, when it gained 17.1%.
- Plus Therapeutics' Non-Current Deffered Revenue stood at $142000.0 in 2019, then jumped by 1057.04% to $1.6 million in 2022, then increased by 17.1% to $1.9 million in 2023.
- Business Quant data shows PSTV's Non-Current Deffered Revenue at $1.9 million in Q4 2023, $1.6 million in Q4 2022, and $142000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.92 Mn |
| Dec 31, 2022 | 1.64 Mn |
| Mar 31, 2019 | 142,000.00 |
| Dec 31, 2018 | 167,000.00 |
| Sep 30, 2018 | 83,000.00 |
| Jun 30, 2018 | 93,000.00 |
| Mar 31, 2018 | 105,000.00 |
| Dec 31, 2017 | 94,000.00 |
| Sep 30, 2017 | 120,000.00 |
| Jun 30, 2017 | 136,000.00 |
| Mar 31, 2017 | 17,000.00 |
| Dec 31, 2016 | 17,000.00 |
| Sep 30, 2016 | 41,000.00 |
| Jun 30, 2016 | 111,000.00 |
| Mar 31, 2016 | 189,000.00 |
| Dec 31, 2015 | 269,000.00 |
| Sep 30, 2015 | 348,000.00 |
| Jun 30, 2015 | 419,000.00 |
| Mar 31, 2015 | 507,000.00 |
| Dec 31, 2014 | 558,000.00 |